Introduction
============

The "cholinergic hypothesis" in aging or Alzheimer's disease is based on the correlation between the memory impairment and the decrease of the cholinergic function in the brain ([@B3]; [@B26]). Such correlation has also been observed in aged rodents ([@B23]; [@B28]). The first clinical approach has thus consisted in inhibiting the decrease of acetylcholine (ACh) by blocking its degradation by acetylcholinesterase (AChE) in the synaptic cleft ([@B31]). Acetylcholinesterase inhibitors (AChEI), such as Donepezil, are currently used in this way but are however modestly effective in AD with only moderate cognitive improvements ([@B29]; [@B22]).

In addition to deficits in ACh, histamine neurotransmission is also reportedly diminished in elderly or in AD ([@B20]). Histamine has raised interest for its implication in memory and attention ([@B40]; [@B36]). Among the four types of histaminergic receptors, the H3 subtype, mainly presynaptic, is expressed on neurons in the central nervous system (CNS), particularly in brain areas involved in cognitive processes and arousal. Expressed on histaminergic neurons, its activation leads to the inhibition of the synthesis and release of histamine ([@B1]) and also negatively regulates the release of other neurotransmitters such as ACh when H3 is expressed on heterologous nerve endings ([@B10]; [@B11]). Thus, it has been argued that H3 antagonists, which could hamper the constitutive negative feedback of H3 receptors on the release of these neurotransmitters, would be valuable in correcting cognitive deficiencies ([@B21]; [@B27]; [@B19]).

To that aim, S 38093 was developed by Servier. S 38093 is an inverse agonist/antagonist of H3 receptors, which has shown procognitive properties at a mean pharmacological dose of 0.3 mg/kg ([@B32]). Indeed, it improves performance in episodic-like memory paradigm both in adult rats (object recognition with natural forgetting or scopolamine-induced amnesia) and aged mice (relational memory task). It is also effective in working memory paradigms in middle-aged mice (spontaneous alternation or concurrent serial alternation) and in aged monkeys (delayed matching to sample task). These effects are thought to be mediated by an enhanced release of neurotransmitters especially ACh and histamine, which are indeed observed by microdialysis in the prefrontal cortex (PFC) and the hippocampus of rats after S 38093 administration ([@B32])

An interesting alternative for treatment of cognitive decline could be to act simultaneously on both histaminergic and cholinergic pathways, to create a synergistic effect. Indeed, combined treatments can be more effective than compounds alone and can allow using lower doses of each compound, i.e., minimizing the potential negative side effects. Therefore, the aim of the present study was to investigate in a first experiment the effect of the chronic administration of S 38093 and Donepezil, alone or in combination, in a model of contextual memory impairments in middle-aged mice ([@B38]). In a second experiment, we measured the cAMP response element binding protein (CREB) phosphorylation as a marker of intracellular PKA activation and increased neuronal activity after behavioral testing. Indeed, it has been shown that memory consolidation relies on PKA activation and subsequent CREB phosphorylation in the hippocampus ([@B9]; [@B16]; [@B4]) whereas cognitive abilities involving mPFC are impaired by PKA activation ([@B34]; [@B2]). Therefore, CREB appears as a point of convergence for the intraneuronal kinase/phosphatase balance, and reflects neuronal activity sustaining memory processes ([@B5]).

Materials and Methods {#s1}
=====================

Animals
-------

Animals were 12 months-old mice of the C57/Bl6 inbred strain obtained from Charles River (L'Arbresle, France). They were housed in collective cage in the colony room (12 h light--dark cycle) until they were 14 months. Three weeks before the experiments, they were housed individually. All procedures were carried out during the light phase of the cycle, between 08:00 a.m. and 12:00 a.m. Three days before the acquisition phase of memory testing and during the remaining behavioral phase, all subjects were maintained at 85--90% of their *ad libitum* body weight. All experiments were performed in accordance with the local Ethics Committee for Animal Experiments and the European Communities Council Directive of 1st February 2013 (2010/63/UE).

Memory Test
-----------

The memory task and apparatus has been fully described previously ([@B13]). The contextual serial discrimination (CSD) task is based on two successive discriminations in a four-hole board which can be retrieved with the help of specific temporal and contextual cues associated with each of them. We already showed that unlike young mice, middle-aged mice showed a deficit in this task ([@B6], [@B7], [@B8]; [@B38]).

### Acquisition Phase

The acquisition phase took place in room A where animals learned two consecutive spatial discriminations (D1 and D2; **Figure [1A](#F1){ref-type="fig"}**) which differed by the color and texture of the floor and were separated by a 2-min delay interval. For both D1 and D2, 10 20-mg food pellets were available during the 6-min exploration sessions; for D2 specifically, the baited hole was consistently located in the opposite symmetrical hole. Environmental cues made of colored paper sheets were positioned at 1.00 m above the board. At the end of the acquisition phase, mice returned in the animal's room for 24 h. Animals retained for the test phase in the present study for both Experiments 1 and 2 have eaten at least 7--8 pellets/10 during both acquisitions.

![**(A)** Contextual serial discrimination: at the acquisition phase, mice performed two consecutive spatial discriminations varying by the color and texture of the floor, i.e., D1: Discrimination 1 and D2: Discrimination 2. For each discrimination, only one hole out of the four holes of the apparatus was baited (hashed circles). The two discrimination were separated by a 2 min delay interval during which animals are placed in room B. A 24-h delay was interpolated between the acquisition and test phases, during which mice were returned in the colony room. 1 h prior to acquisition and test phases, mice received a *per se* administration of the compounds or vehicle solution in a chamber placed in a room (room C) different from the one in which the behavioral experiments was conducted (room A). Subsequently, mice were submitted to the test phase in which they were replaced on the floor of the first discrimination without any food pellet in the apparatus. **(B)** Two types of responses were calculated: (i) correct responses corresponding to head-dips into the hole baited at the acquisition of the first discrimination (D1), on the same floor context; (ii) interference responses corresponding to head-dips into the hole baited at the other (second) discrimination (D2). These two parameters allow calculus of the SCM score.](fphar-07-00492-g001){#F1}

### Test Phase

Mice were replaced on the D1 floor in the board without any pellet in the apparatus and were allowed to freely explore for 6 min during which the number of head-dips in each hole was counted. This allowed measures of the % of "correct responses" (head-dips into the hole previously baited on the same floor-context), the % of "interference responses" (head-dips into the hole previously baited at D2, on the other floor-context) (**Figure [1B](#F1){ref-type="fig"}**) and of the "strength" of "contextual memory" score (SCM) (% correct responses - % interference responses). Thus, since correct responses are based on the use of the internal context (color of the floor) and interferent responses are based on the use of spatial allocentric cues previously associated with the other floor, thus the trend of SCM score toward a positive difference represents the gain of internal contextual memory, at the expense of allocentric spatial one.

Experiment 1: Effect of the Compounds and Their Combinations on Age-Related Memory Deficit
------------------------------------------------------------------------------------------

### Drug Administration

S 38093 (Servier, France) and Donepezil (Syntheval, France) are hydrochloride salts. S 38093 belongs to the chemical family of benzamides, its hydrochloride salt S 38093-2 (called S 38093 in the paper) was used in this study. Its chemical formula is C~17~H~24~N~2~O~2~, HCl (**Figure [2](#F2){ref-type="fig"}**).

![**Chemical formula of S 38093 (C~17~H~24~N~2~O~2~, HCl)**.](fphar-07-00492-g002){#F2}

S 38093 and Donepezil were diluted in purified water. Mice were allocated to administration of vehicle (purified water), S 38093 (*S1*: 0.1 mg/kg; *S2*: 0.3 mg/kg; *S3*: 1.0 mg/kg) or Donepezil (*Don1*: 0.1 mg/kg; *Don2*: 0.3 mg/kg), or a combination of both S 38093 and Donepezil at the same doses with *N* = 12 in each group. S 38093 and Donepezil doses were determined according to previous data ([@B7]; [@B32]). Before behavioral testing, all mice received for nine consecutive days a daily esophageal administration of S 38093, Donepezil, vehicle or S 38093 + Donepezil combinations, administered at a volume of 10 mL/kg. The two last administrations were delivered 1 h before the acquisition and test phases.

### Pharmacokinetics Study

For the pharmacokinetics study, an additional day of treatment (day 10) was done for blood sampling to measure concentrations of S 38093 and Donepezil in plasma, on the combinations groups where either the most important synergistic effect was observed, or containing the highest doses of S 38093 and Donepezil. Then, blood sampling (250 μL /sample) was performed on five groups (*N* = 3 animals per group): S 38093 (0.1 and 1.0 mg/kg); Donepezil (0.3 mg/kg); combination of Donepezil (0.3 mg/kg); and S 38093 (0.1 and 1.0 mg/kg). The sampling times are 30 min, 1, 2, 4, and 6 h. In each mouse, two time points of blood sampling were performed. Plasma was extracted from the blood sample by centrifugation (+4°C, 3000 *g*, 10 min) and stored at -80°C. Then, plasma samples were sent in dry ice to MDS (MDS Pharma Services, Switzerland) for the pharmacokinetic analysis.

S 38093 and Donepezil were independently measured by liquid chromatography using tandem mass spectrometry detection (LC/MS--MS). Prior to analysis, S 38093 was extracted from 25 μL of sample by solid phase extraction on an Isolute 96 CBA SPE 50 mg cartridge while Donepezil was extracted by liquid/liquid extraction from a second 25 μl aliquot. The limit of quantification was 0.3 ng/mL for S 38093 and 0.1 ng/mL for Donepezil.

Animals were sacrificed by cervical elongation immediately after either behavioral testing or plasma sampling.

Experiment 2: Study of the Effects of the Compounds on Age-Related Memory Deficit and CREB Phosphorylation
----------------------------------------------------------------------------------------------------------

### Behavioral Testing

Food deprivation, drug administration and behavioral testing procedures were similar as in Experiment1. We performed in Experiment 2 an immunohistochemical study on the combination groups where either the most important synergistic effect was observed (Don2+S1 and Don2+S2), or Vehicle, S 38093 and Donepezil alone (Vehicle, S1, S2, and Don2). Independent groups of mice (*N* = 10 per group) were used. An additional group composed by young vehicle mice (4--5 months young-vehicles, *N* = 10) was added for determination of the aging effect on both memory and phosphorylated CREB immunoreactivities, as compared to middle-aged Vehicles. For the immunohistochemical study, animals submitted to D1 memory testing were compared to "naïve" mice isolated in the colony room (with *N* = 5 per group; Naïve condition) and that underwent the food deprivation procedure and drug treatments as behaving animals (Test condition).

### Immunohistochemistry

Thirty minutes after completion of the test session, mice were deeply anesthetized (Avertin, 10 mL/kg intraperitoneally i.p.), and perfused transcardially with an ice-cold solution of 4% paraformaldehyde in phosphate buffer (0.1 M, pH 7.4). After perfusion, brains were removed and post-fixed overnight in the same fixative at 4°C. Brains were then put in a sucrose solution (30% in Tris Buffer 0.1 M, pH 7.4) during 24 h. They were then frozen and cut in 50-mm coronal free-floating sections with a freezing microtome (Leica) to proceed to immunochemistry.

Total CREB (tCREB) and phosphorylated CREB (pCREB) immunostainings were performed as described in full previously ([@B39]; [@B18], [@B17]). Countings were made in the following brain regions according to [@B33] atlas: the CA1 of the dorsal (dCA1) and ventral (vCA1) hippocampus, the prelimbic cortex (PL), the dorsal striatum (St), the basolateral amygdala nucleus (BLA) and the medial septum nucleus (MS). Digital images were captured at 10X magnification using an Olympus (BX50) and an imaging analysis system (ImageJ^®^). At least six serial sections for each brain region were analyzed using a computerized image analysis system (Visiolab 2000^®^, Biocom, and V4.50). Quantification was expressed as mean number of positive nuclei per mm^2^.

Statistical Analysis
--------------------

Behavioral data were analyzed by one-way or two-way factorial analyses of variance, followed when adequate, by *post hoc* (Dunnett test) comparisons using the least significant difference test, with a *p* \< 0.05 statistical threshold. Data were represented as mean ± standard-error of the mean. For correlation analyses, the Spearman's correlation coefficient, R, was determined. For immunohistochemistry, in so far as no difference was found in the naïve condition, data were analyzed similarly using the rough number of immunopositive cells, with a *p* \< 0.05 statistical threshold.

Results
=======

EXPERIMENT 1
------------

### Effect of the Compounds and Their Combinations on Age-Related Memory Deficit

Body weights among the groups were ranged from 28.9 ± 3.5 to 32.4 ± 4.3 g and no significant between-groups difference was observed \[*F*(11,132) \< 1.0\]. During the food restriction period, both vehicles and drug-treated mice eaten all their allocated daily amount of dry food. All animals retained for the test session have eaten at least 7/8 pellets out of 10 at both the first and second acquisitions.

#### Acquisition phase

No significant difference was observed among the groups on the total number of head-dips as well as on the % exploration of the baited hole both at acquisitions 1 and 2 (*p* \> 0.10 in all analyses).

#### Test phase

*Total number of head-dips*. The total number of head-dips ranged from 31.2 ± 9.4 to 62.3 ± 9.4 and no significant between-groups difference was observed \[*F*(11,132) \< 1.0\]. The interaction (S 38093 X Donepezil) was also not significant \[*F*(6,132) = 0.54, *p* = 0.780\]. Thus, the dose effect of S 38093 or Donepezil has been analyzed at all levels pooled of the other drug. There was no significant effect of either S 38093 \[*F*(3,132) = 1.45, *p* = 0.231\] or Donepezil \[*F*(2,132) = 0.28, *p* = 0.760\] on this parameter.

*Strength of contextual memory (SCM)*. Data are presented in **Figure [3](#F3){ref-type="fig"}**. A one-way analysis of variance (ANOVA) showed a highly significant between-groups difference \[*F*(11,132) = 9.76; *p* = 0.0001\]. For compounds alone, S 38093 at 0.1 and 1.0 mg/kg and Donepezil at all doses did not show significant effect on the SCM scores as compared to the vehicle group (*p* \> 0.10). For combinations of compounds, except the combination of the two lowest (Don at 0.1 mg/kg and S 38093 at 0.1 mg/kg) and the two highest doses (Don at 0.3 mg/kg and S 38093 at 1.0 mg/kg) of each compound, there was a strong, significant increase of SCM scores (*p* \< 0.01, *p* \< 0.001, *p* \< 0.001, and *p* \< 0.01, respectively).

![**Effects of S 38093, Donepezil and combinations on SCM scores in middle-aged mice (Experiment 1).** SCM scores are expressed as mean ± SE. SCM scores are obtained by calculation (% of correct responses -- % of interferent responses). As can be seen, the lowest S 38093 dose combined with the highest Donepezil dose (DON 2 + S1), and inversely (DON 1 + S3), significantly increased SCM scores as compared to Vehicle and compounds alone. ^∗∗^*p* \< 0.01 and ^∗∗∗^*p* \< 0.001 as compared to vehicle; ^\#\#^*p* \< 0.05 and ^\#\#\#^*p* \< 0.01 respectively as compared to compounds alone.](fphar-07-00492-g003){#F3}

### Pharmacokinetics Interaction

Results have been summarized in **Table [1](#T1){ref-type="table"}**. The inter-individual variability on S 38093 plasma concentrations was moderate. Cmax was reached 0.5 h after dosing and the elimination half-life was between 1.5 and 2.4 h. Both exposure and C~max~ increase in a dose proportional manner within the same treatment regimen.

###### 

Mean pharmacokinetic parameters of S 38093 (0, 0.1, and 1.0 mg/kg) and Donepezil (0.3 mg/kg), given alone or in combination in middle-aged mice (five groups, *n* = 3/group).

             Dose            0      0.1    1              
  ---------- --------------- ------ ------ ------ ------- -------
  S 38093    AUC (ng.h/mL)   --     9.56   3.69   92.40   53.90
             Cmax (ng/mL)    --     3.04   1.27   55.6    36.30
             Tl/2(h)         --            1.51   2.37    1.54
             Tmax(ll)        --     2.0    0.5    0.5     0.5
                                                          
             Dose            0.3    0      0.3    0       0.3
                                                          
  Donepezi   AUC (ng.h/mL)   2.79   --     0.90   --      1.55
             Cmax (ng/mL)    0.96   --     0.48   --      1.11
             Tmax(ll)        1.0    --     0.5    --      0.5

The PK parameters of the co-administration of S 38093 (0.1 and 1.0 mg/kg) with Donepezil (0.3 mg/kg) are in the gray columns.

Variability of Donepezil plasma concentrations following concomitant administration of 0.3 mg/kg was moderate. Maximal Donepezil plasma concentrations were observed between 0.5 and 1 h after administration and were similar with and without co-administration of S 38093. There was no increase of neither S 38093 nor Donepezil plasma exposure when administered as a combination.

Experiment 2: Study of the Effect of the Compounds on Age-Related Memory Deficit and CREB Phosphorylation
---------------------------------------------------------------------------------------------------------

Body weights among the groups were ranged from 25.9 ± 2.8 g (young adult mice) to 31.6 ± 4.1 g and no significant between-groups difference was observed (*p* \< 0.12). During the food restriction period, both vehicles and drug-treated mice eaten all the allocated daily amount of dry food. As in Experiment 1, all animals retained for the test session have eaten at least 7/8 pellets out of 10 at both the first and second acquisitions.

### Effects of Aging on SCM Score and pCREB Activity

#### Behavior

*Acquisition phase*. No significant difference was observed among the groups on the total number of head-dips as well as on the % exploration of the baited hole both at acquisitions 1 and 2 \[*F*(1,18) \< 1.0 in all analyses; data not shown\].

#### Test session

*Effects of aging on SCM scores*. Results are presented in **Figure [4A](#F4){ref-type="fig"}**. Young adults and middle-aged animals exhibited a similar total number of head-dips at the test session \[30 ± 4.26 and 25.5 ± 4.05, respectively; Groups: *F*(1,18) \< 1.0\]. However, young mice exhibited a positive score (+20.0 ± 3.6) whereas middle-aged animals exhibited a negative one (-18.9 ± 7.9) \[Groups; *F*(1,18) = 18.92; *p* = 0.0004\].

![**(A)** Effects of aging on SCM scores (Experiment 2). As can be seen, 14 months-old middle-aged mice exhibited a significant reduction of SCM score as compared to 5 months-old young-adult mice. Between-groups difference: ^∗∗∗^*p* \< 0.001. **(B)** Effects of aging on pCREB immunoreactivities. Counting was made in the PFC, dCA1, vCA1, medial septum, dorsal striatum, and BLA. No significant differences were observed between the groups in all brain areas in naïve condition (data not shown). Middle-aged mice showed reduced behavioral testing-related pCREB immunoreactivities in the dCA1, vCA1, and medial septum as compared to young adult mice. In contrast, a significant increase of pCREB was observed in the BLA in middle-aged animals, as compared to young ones. Results are expressed as mean number of positive pCREB nuclei per mm^2^. ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01.](fphar-07-00492-g004){#F4}

#### Immunohistochemistry

*Effects of aging on tCREB and pCREB immunoreactivity*. Results are presented in **Figure [4B](#F4){ref-type="fig"}**. One way ANOVA evidenced no significant difference (*p* \> 0.10 in all analyses) between young adult and middle-aged mice on the number of tCREB immunopositive cells in naïve and test conditions, whatever the brain areas counted (data not shown). Concerning pCREB, one way ANOVA also evidenced no significant between-groups difference in naïve condition on pCREB scores whatever the brain areas counted (*p* \> 0.10 in all analyses; data not shown).

### Effects of Treatments on SCM Scores and pCREB Activity in Middle-Aged Mice

#### Behavior

The group of young adult mice has been discarded from further statistical analyses since the effects of the compounds alone or in combination have been studied only in middle-aged animals.

*Acquisition phase*. No significant difference was observed among the groups on the total number of head-dips as well as on the % exploration of the baited hole both at acquisitions 1 and 2 \[*F*(1,54) \< 1.0 in all analyses; data not shown\].

#### Test phase

*Total number of head-dips*. A significant between-groups difference is observed \[*F*(5,54) = 2.95; *p* = 0.02\] being mainly due to the S 0.3 mg/kg (44.90 ± 6.56) and S 0.1 mg/kg (37.4 ± 6.15) groups. However, *post hoc* analyses failed to reach the statistical level of significance for these two groups as compared to either vehicles (25.50 ± 4.05; *p* \> 0.10) or Don 0.3 mg/kg (23.90 ± 4.06; *p* \> 0.15). The groups receiving the doses combinations (Don 0.3 mg/kg+ S 0.1 mg/kg: 21.90 ± 3.42; Don 0.3 mg/kg + S 0.3 mg/kg: 29.10 ± 6.06) exhibited a total number of head-dips similar to that of vehicles (*p* \> 0.10).

*Strength of contextual memory*. Data are represented in **Figure [5](#F5){ref-type="fig"}**. ANOVA evidenced significant effects of Donepezil \[*F*(1,54) = 48.88; *p* \< 0.0001\], of S 38093 \[*F*(2,54) = 7.49; *p* = 0.0013\] and of the interaction between Donepezil and S 38093 \[*F*(2,54) = 5.57; *p* = 0.0063\]. Donepezil (+7.48 ± 3.60) and S 38093 at the doses of 0.3 mg/kg (+5.19 ± 6.68) and 0.1 mg/kg (-14.3 ± 5.76) produced no significant modifications of the scores as compared to vehicle (-18.14 ± 7.9; NS in all comparisons). However, the higher positive scores were observed in groups receiving the combinations of Donepezil and S 38093 at the doses of 0.1 mg/kg (+43.59 ± 7.10; *p* \< 0.001 versus vehicle and *p* \< 0.01 versus the Donepezil group) and 0.3 mg/kg (+25.73 ± 3.96; *p* \< 0.01 versus vehicle; NS versus Donepezil). Thus, only the combination of Donepezil and S 38093 at 0.1 mg/kg produced a significant increase of SCM score as compared to both vehicle-treated mice and Don 0.3 mg/kg.

![**Effects of S 38093, Donepezil and combinations on SCM scores in middle-aged mice (Experiment 2).** SCM scores are expressed as mean ± SE. SCM scores are obtained by calculation (% of correct responses -- % of interferent responses). As can be seen, the lowest S 38093 dose combined with Donepezil significantly increased SCM scores as compared to Vehicle and compounds (Donepezil and S 38093) alone. Combination of Donepezil and the higher S 38093 dose induced a significant increase of SCM score as compared to vehicle only. ^∗∗^*p* \< 0.01 and ^∗∗∗^*p* \< 0.001 as compared to vehicle; \#\#*p* \< 0.01 as compared to Donepezil and S 38093 alone.](fphar-07-00492-g005){#F5}

In contrast, significant differences were observed in test condition (**Figure [5](#F5){ref-type="fig"}**). More specifically, middle-aged mice exhibited less immunopositive cells as compared to young animals in the dCA1 (-47.5%; *p* = 0.007), the vCA1 (-56%; *p* = 0.0037), and the MS (-66.2%; *p* = 0018). A weak increase of immunopositive cells is observed in the BLA of middle-aged mice (+32.7%; *p* = 0.039). No significant between-groups difference was observed in the PFC and the dorsal striatum.

#### Effects of treatments on tCREB and pCREB immunoreactivity in middle-aged mice

*Total CREB*. Analysis of variance analyses showed no significant between-groups difference, no treatments effect and no significant interaction between drugs were found both in naïve and test conditions (*p* \> 0.10 in all analyses; data not shown).

*Phosphorylated CREB*. In naïve condition, no significant between-groups difference, no treatments effect and no significant interaction between drugs was found whatever the brain structure counted (*p* \> 0.10 in all analyses; data not shown).

In test condition (**Figure [6A](#F6){ref-type="fig"}**), no significant between-groups difference and no significant interaction between drugs were observed in the BLA, the dorsal striatum and the vCA1 (*p* \> 0.10 in all analyses). However, donepezil induced a significant increase of immunopositive cells in the dCA1 \[*F*(1,54) = 11.2; *p* \< 0.001\] and in the MS \[*F*(1,54) = 18.3; *p* \< 0.001\]. S 38093 at both doses has no significant effect in these two brain areas. Two way ANOVA also showed that S38093 and Donepezil have a significant interaction effect in the dCA1 \[*F*(2,54) = 3.57; *p* \< 0.03\] and the interaction is near from statistical significance in the MS \[*F*(2,54) = 3.0; *p* = 0.058\]. **Figure [6B](#F6){ref-type="fig"}** illustrated changes in pCREB activity in the dCA1 of the hippocampus in the different groups in naïve and test conditions.

![**Effects of S 38093, Donepezil and combinations on pCREB immunoreactivities in middle-aged mice. (A)** Counting was made in the PFC, dCA1, vCA1, medial septum, dorsal striatum, and BLA. No significant differences were observed between the groups in all brain areas in naïve condition (data not shown). As can be seen, the lowest S 38093 dose combined with Donepezil significantly increased pCREB immunopositive cells as compared to vehicles and compounds (Donepezil and S 38093) alone. A significant increase of immunopositive cells was also observed in the BLA with the same combination as compared to compounds alone (Donepezil or S 38093). Combination of Donepezil and the higher S 38093 dose induced a significant increase of pCREB immunopositive cells as compared to vehicles only. ^∗^*p* \< 0.05 and ^∗∗∗^*p* \< 0.001 as compared to vehicles; \#\#*p* \< 0.01 as compared to Donepezil and ^∙^*p* \< 0.05 as compared to S 38093 alone. **(B)** Representative photomicrographs showing pCREB immunoreactivities in the dCA1 of the hippocampus in young adult and middle-aged mice after administration of S 38093 (0.1 and 0.3 mg/kg), Donepezil (0.3 mg/kg) and combinations both in naïve and test conditions. Magnification X20, Scale bar: 50 μm.](fphar-07-00492-g006){#F6}

Calculus in percentage of the enhancement of pCREB in the combination groups as compared to compounds alone or vehicles were performed. The main findings are as follows:

*In the BLA*, Dunnett *post hoc* test evidenced a significant increase of pCREB expression in mice receiving S 0.1 mg/kg +Don 0.3 mg/kg (+60.9%) in comparison with S 0.1 mg/kg alone (*p* \< 0.01).

*In the dCA1*, results showed a significant increase of pCREB expression in mice receiving the combination S 0.1 mg/kg+ Don 0.3 mg/kg (+129.4%) and in mice receiving S 0.3 mg/kg+ Don0.3 mg/kg (+64.7%; *p* \< 0.01) as compared to vehicle. More importantly, for the group receiving the combination S 0.1 mg/kg+Don0.3 mg/kg, a significant increase of pCREB expression of +192.7% has been evidenced as compared to S 0.1 mg/kg alone (*p* \< 0.01) and of +137.1% in comparison with Donepezil alone (*p* \< 0.01).

*In the MS*, Donepezil alone as well as the combination S 0.1 mg/kg+ Don 0.3 mg/kg induced a significant increase of pCREB expression of +174.3% and +214.1% respectively as compared to vehicle. A significant increase of +380.7% has also been evidenced between S 0.1 mg/kg alone and the combination S 0.1+ Don 0.3 mg/kg.

Discussion
==========

Synergistic Effects between Donepezil and S 38093 on Contextual Memory in Middle-Aged Mice
------------------------------------------------------------------------------------------

As regards SCM scores, vehicle-treated middle-aged mice showed a negative score on the retention of D1 (indicating an increase of interferent responses) in sharp contrast to young adult mice which exhibited a very positive score. In contrast, compounds alone or in combination (excepted for the combinations of the two lowest and the two highest doses of each compound) reverse this age-related memory pattern, as those mice have a substantial memory of D1 but not of D2 as compared to vehicle-treated animals. Since it has been shown that memory of D1 is hippocampus-dependent ([@B12], [@B14]) whereas memory of D2 is dependent on the PFC activity ([@B13]), it is thus of importance to verify that any promnesiant impact of the combinations of compounds on D1 did not alter memory of D2. This effect, statistically significant for the combinations with the exception quoted above, is the index of a substantial contextual memory-enhancing effect since the increase of the correct response is accompanied by a concomitant decrease of the interference one. Interestingly, the more powerful combination is observed with the lowest S 38093 dose + Donepezil 0.3 mg/kg since this combination induced a significant enhancement of contextual memory as regards to both Donepezil and S 38093 alone. It is noteworthy that combination of S 38093 with low pro-cognitive doses of any other compound currently approved for moderate-to-severe AD \[i.e., others AChEI (rivastigmine and galantamine) and memantine, an uncompetitive NMDA (*N*-methyl-[D]{.smallcaps}-aspartate) antagonist\] also leads to higher reversal of age-related memory deficit in this task compared to compounds alone (unpublished results, data not shown). Moreover, there was a very good correlation between the increase of percentage of correct responses and the decrease of percentage of interferent responses, confirming the specific effect of each compound and their combinations on contextual memory (data not shown).

Interestingly, a synergistic effect between a H3 antagonist and an anti-cholinesterase inhibitor has also been described in cognitive impairment associated with scopolamine in healthy young subjects ([@B15]). Our data showing synergistic effects between the H3 antagonist S 38093 and drugs approved in AD are innovative since, to our knowledge, that has never been described for other H3 compounds nor procognitive compounds on natural model of age-induced amnesia in rodents.

As the two compounds were administered simultaneously, it was important to assess a potential pharmacokinetic interaction, which could have faked a synergistic effect by increasing the blood exposure. Our study confirmed that the synergistic effect of the combination of the two compounds is not due to a pharmacokinetic interaction between them. Moreover, the safety of S 38093 and Donepezil, alone or in combination, was tested using the primary observation (IRWIN) test in mice and results showed that the combination of pharmacological doses of both compounds did not induce any observable clinical signs, similarly as compounds administered alone (data not shown).

Synergistic Effects between Donepezil and S 38093 on pCREB Immunoreactivity in the Dorsal Hippocampus and the Medial Septum
---------------------------------------------------------------------------------------------------------------------------

Aging reduced pCREB in the dCA1, the vCA1 and the MS as compared to young vehicle, whereas an increase of pCREB is observed in the BLA. These data confirm that alterations of the hippocampus activity induced contextual memory deficit in middle-aged animals ([@B8]). Interestingly, we also previously showed that the BLA and the mPFC are importantly involved in the memory retrieval of D2 ([@B13]; [@B18]). Thus, the increase of pCREB in the BLA during memory retrieval of D1 could reflect an abnormal concomitant recruitment of a BLA-PFC network in middle-aged animals which could increase interference (D2) responses.

Whereas no significant between-groups difference is observed in the naive condition, S 38093 and Donepezil have a significant synergistic effect in the dCA1 and near significant effect in the MS, as compared to each compound alone. More precisely, the combination of S 0.1 mg/kg and Donepezil 0.3 mg/kg reverses in the dCA1 the age-induced hypo-phosphorylation of pCREB. This combination is also the most efficacious in reversing the age-induced memory retrieval deficit for D1, as previously reported.

Hypothesis on the Mechanism of Action
-------------------------------------

Immunohistochemical data show that the combination of S 0.1 mg/kg and Don 0.3 mg/kg increases pCREB in structures of the cholinergic septo-hippocampal loop. Indeed, the medial septal area provides most of the cholinergic innervation of the hippocampus ([@B25]; [@B30]).

Thus, one hypothesis regarding the mechanisms of action of the compounds is an effect on the hippocampal cholinergic system. Indeed, in separate experiments, we showed that the acute as well as chronic administration of S 38093 in rats, by antagonizing presynaptic H~3~ receptors, has been shown to rapidly and dose-dependently increase the release of ACh in the ventral hippocampus and the PFC of rats (intracerebral microdialysis, see supplemental data and [@B32]). On the other hand, the well-known AChEI Donepezil, given alone, also increased ACh level in the synaptic cleft after acute administration. Previous studies have also confirmed that the increase in ACh levels induced by Donepezil in the cortex and hippocampus of rats are maintained after chronic administration ([@B35]). Either action could result in the observed enhancement of contextual memory with compounds alone, whereas the stronger effect of the combinations could be attributed to a synergistic effect on the hippocampal cholinergic system, including the additive effect on ACh release of the compounds observed in microdialysis when S 38093 and Donepezil were administered together (Supplemental Data, see Figures [1](#SM2){ref-type="supplementary-material"} and [2](#SM3){ref-type="supplementary-material"}). Thus the microdialysis experiment evidenced the potential capacity of S 38093 and Donepezil to enhance the cholinergic activity within the hippocampo-PFC network that is substantially implicated in the CSD task.

Even if the effect of the compounds were evaluated in the PFC and the ventral hippocampus in supplemental data, it was also demonstrated that H3 antagonists including S 38093 (data no shown) as well as Donepezil were also able to significantly increase ACh levels in other brain areas and in particular dorsal hippocampus ([@B41]; [@B24]), a critical region for memory processes, in which we have demonstrated pCREB increases in the present study.

Mice treated with the combination of the two highest doses of S 38093 and Donepezil showed impairments in the retrieval of D1. It could be hypothesized that this combination induces an important increase of acetylcholine levels both in the hippocampus and PFC, which could alter the interaction between these two areas during the testing of D1, leading to memory impairment. Indeed, the concomitant recruitment of the PFC by acetylcholine in mice receiving the drug combinations could enhance interference (D2) responses ([@B13]), at the expense of the dHPC-dependent one (D1).

Conclusion
==========

The present study shows that the combination of the two memory-enhancing compounds, Donepezil and the H~3~ antagonist S 38093, can lead to synergistic memory-enhancing effects, with a statistically higher size of effect never obtained with any memory-enhancing compounds alone without any pharmacokinetic interaction between both compounds. The memory-enhancing effect of the S 38093 and Donepezil combination is mediated by its action on the septo-hippocampal circuitry, since it canceled out the hypo-phosphorylation of pCREB in both the dCA1 and the medial septum that is observed in vehicle-treated middle-aged mice. Given the known pro-cholinergic effects of histaminergic H3 inverse agonists and Donepezil ([@B37]) and our own data drawn from the microdialysis experiment (supplemental data), it could be suggested that the synergistic effects of the combination of S 38093 and Donepezil on memory performance in middle-aged mice could stem from an enhancement of the septo-hippocampal cholinergic system.
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